openPR Logo
Press release

Erectile Dysfunction Market is expected to reach USD 6.5 billion by 2034, driven by rising consumer awareness and treatment demand

06-16-2025 09:25 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Exactitude Consultancy

Erectile Dysfunction Market

Erectile Dysfunction Market

The erectile dysfunction (ED) market is projected to be valued at $4 billion in 2024, driven by factors such as increasing consumer awareness and the rising prevalence of industry-specific trends. The market is expected to grow at a CAGR of 5.5%, reaching approximately $6.5 billion by 2034.

Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Erectile Dysfunction market goods. The market study excludes key regions that are accelerating marketization. This section also gives the extent of different market segments and applications that could have an impact on the market in the future. Current trends and historical turning points form the basis of the enormous amount of data. The report includes information on market trends and development, growth drivers, emerging technologies, and the investment structure of the Erectile Dysfunction market.

This report is also available in the following languages : Japanese (勃起不全), Korean (발기부전), Chinese (勃起功能障碍), French (Dysfonction érectile), German (Erektile Dysfunktion), and Italian (Disfunzione erettile), etc.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/61509

Key Companies:
Pfizer Inc., Eli Lilly and Company, Bayer AG, AbbVie Inc., GlaxoSmithKline plc, Teva Pharmaceuticals, Aytu BioScience, Ferring Pharmaceuticals, Hims & Hers Health, Inc., Bosch Healthcare Solutions, Mylan N.V., Zydus Cadila, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Amgen Inc.

Market Segmentation
By Product Type
Oral Medications
Vacuum Pumps
Injections
Implants

By Application
Psychogenic ED
Organic ED

By End User
Hospitals
Clinics
Home Care Settings

By Technology
Pharmacological
Non-Pharmacological

By Distribution Channel
Pharmacies
Online Stores
Hospitals

Explore Full Report here: https://exactitudeconsultancy.com/reports/61509/global-erectile-dysfunction-market

If opting for the Global version of Erectile Dysfunction Market; then the below country analysis would be included:

- North America (the USA, Canada, and Mexico)
- Europe (Germany, France, the United Kingdom, Netherlands, Italy, Nordic Nations, Spain, Switzerland, and the Rest of Europe)
- Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India, Southeast Asia, and the Rest of APAC)
- South America (Brazil, Argentina, Chile, Colombia, the Rest of the countries, etc.)
- the Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Turkey, Nigeria, South Africa, Rest of MEA)

Buy Now @ https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=61509

The report provides insights on the following pointers:
Market Penetration: Comprehensive information on the product portfolios of the top players in the Erectile Dysfunction market.
Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.
Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Erectile Dysfunction market.

Get Your Exclusive Offer with up to 30% Discount : https://exactitudeconsultancy.com/check-discount/61509

Reasons To Buy The Erectile Dysfunction Market Report:

➼ In-depth analysis of the market on the global and regional levels.
➼ Major changes in market dynamics and competitive landscape.
➼ Segmentation on the basis of type, application, geography, and others.
➼ Historical and future market research in terms of size, share growth, volume, and sales.
➼ Major changes and assessment in market dynamics and developments.
➼ Emerging key segments and regions
➼ Key business strategies by major market players and their key methods

Our team is available 24/7 to assist and support our customers through reliable research.

Customization
-20% free customization.
-Five Countries can be added as per your choice.
-Five Companies can added as per your choice.
-Free customization up to 40 hours.
-Post-sales support for 1 year from the date of delivery.

Other Reports:

Multiplex Immunofluorescence Assay Market
https://exactitudeconsultancy.com/reports/62855/global-multiplex-immunofluorescence-assay-market

DevOps Market
https://exactitudeconsultancy.com/reports/62896/global-devops-market

Microcontroller Market
https://exactitudeconsultancy.com/reports/62936/global-microcontroller-market

Alginate Impression Materials Market
https://exactitudeconsultancy.com/reports/62976/global-alginate-impression-materials-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Erectile Dysfunction Market is expected to reach USD 6.5 billion by 2034, driven by rising consumer awareness and treatment demand here

News-ID: 4067677 • Views:

More Releases from Exactitude Consultancy

Relapsed/Refractory Acute Myeloid Leukemia Market is expected to reach USD 6.1 billion by 2034
Relapsed/Refractory Acute Myeloid Leukemia Market is expected to reach USD 6.1 b …
Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow and blood. Despite advances in frontline therapies, relapse is common, and many patients develop refractory disease, leaving limited treatment options and poor survival outcomes. Relapsed/refractory AML (R/R AML) remains a major unmet clinical need. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71571 In recent years, however, the
Retinoblastoma Market to Reach USD 1.2 Billion by 2034
Retinoblastoma Market to Reach USD 1.2 Billion by 2034
Retinoblastoma is a rare pediatric eye cancer that originates in the retina and primarily affects children under five years of age. It accounts for around 3% of all childhood cancers but is the most common intraocular malignancy in children. With improved awareness, early screening, and advances in treatment, survival rates in developed nations exceed 90%. However, challenges remain in low- and middle-income countries where delayed diagnosis and limited access to
Severe Toxicities in Lymphoma Market Projected to Reach USD 3.7 Billion by 2034
Severe Toxicities in Lymphoma Market Projected to Reach USD 3.7 Billion by 2034
Lymphoma, a group of blood cancers affecting the lymphatic system, is broadly classified into Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). While survival outcomes have improved significantly with chemotherapy, radiotherapy, targeted agents, and immunotherapies, many patients experience severe toxicities as side effects of treatment. These toxicities - ranging from cytokine release syndrome (CRS) and neurotoxicity in CAR-T therapy to myelosuppression, infections, and organ toxicities from chemotherapy and immunomodulators - can
Soft Tissue Neoplasms Market to Reach USD 6.0 Billion by 2034
Soft Tissue Neoplasms Market to Reach USD 6.0 Billion by 2034
Soft tissue neoplasms are abnormal growths arising from connective tissues, including muscles, fat, nerves, tendons, and blood vessels. While some are benign, malignant forms such as soft tissue sarcomas (STS) pose serious clinical challenges due to their aggressive nature, rarity, and diverse histological subtypes. Representing about 1% of all adult cancers, these neoplasms require a wide spectrum of treatments ranging from surgery and radiotherapy to chemotherapy and novel targeted therapies. Download

All 5 Releases


More Releases for Erectile

Erectile Dysfunction Drugs Market Beyond the Bedroom: The Impact of Erectile Dys …
Erectile Dysfunction Drugs Market to reach over USD XX billion by the year 2031 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Drug (Avanafil (Stendra), Muse Suppository (Alprostadil), Sildenafil (Viagra)), Mode of Administration (Injections, Oral, Topical), Distribution Channel (hospital pharmacies, online pharmacies, and retail pharmacies), Region, Market
Global Erectile Dysfunction Devices Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Erectile Dysfunction Devices Market is projected to grow at a CAGR of 9.6% from 2023 to 2028. The market is driven by the increasing prevalence of erectile dysfunction amongst young men, advancements in medical technology, growing awareness and acceptance, the aging population, and strategic collaborations. Browse 147 Market Data Tables and 115 Figures spread through 163 Pages
Erectile dysfunction drugs market to Surpass erectile dysfunction drugs market | …
Global Erectile Dysfunction Drugs Market size was valued at USD 2130 million in 2021 and is projected to reach USD 3250 million by 2028, growing at a CAGR of 5.4% from 2021 to 2028 according to a new report by Intellectual Market Insights Research. Get Sample Report:https://www.intellectualmarketinsights.com/download-sample/IMI-003946 Scope of Erectile Dysfunction Drugs Market Report: A recent market research report added to repository of Intellectual Market Insights Research is an in-depth analysis of Global
Global Erectile Dysfunction Devices Market Report
As per GME studies, on the Global Erectile Dysfunction Devices Market, it is analyzed that the market will grow at a CAGR of 6.5%. Erectile dysfunction incidence increases with growing age, about 5-10% of men under 40 years are the possible suspects for the dysfunctionality. This is projected to drive the ED device market in the coming years also. Raising the aforementioned disease prevalence and the growing percentage of tobacco
Erectile Dysfunction Drugs Market Size, Erectile Dysfunction Drugsmarket Share, …
According to a new study published by Polaris Market Research the global erectile dysfunction drugs market is anticipated to reach USD 2.63 billion by 2025. Request for Sample of This Research Report @ https://bit.ly/2NXzatD Top Key Players:- Bayer AG Pfizer Eli Lilly & Co. Vivus, Inc. S.K. Chemicals Co. Ltd. Dong-A Pharmaceutical Co. Ltd Meda Pharmaceuticals Apricus Biosciences Make an inquiry before buying this report @ https://www.polarismarketresearch.com/industry-analysis/erectile-dysfunction-drugs-market/inquire-before-buying According to a new study published by Polaris Market Research the global erectile dysfunction
Erectile Dysfunction Market Industry Forecast till 2024
Erectile dysfunction is known as the medical condition of penis, a recurrent inability of a man to reach and/or to maintain a penile erection sufficient for/during sexual activities. It is most probably an age-related factor, progressive condition, affecting some level of disorder (mild, moderate or severe) in about 50% of men aged 40-70 years, and with the increase in the age, severity of erectile dysfunction also increase with a